Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to l-dopa: levodopa, dopamine, Mucuna pruriens


a compound produced by oxidation of tyrosine by tyrosinase; it is the precursor of dopamine and an intermediate product in the biosynthesis of norepinephrine, epinephrine, and melanin. The naturally occurring form is l-dopa (see levodopa), and is used to treat parkinson's disease and other forms of parkinsonism.


The biologically active form of dopa; an antiparkinsonian agent that is converted to dopamine.
Synonym(s): l-dopa


An isomer of dopa that is converted in the brain to dopamine and is used in synthetic form to treat Parkinson's disease. Also called levodopa.


Abbreviation for levodopa.

Levodopa (L-dopa)

A substance used in the treatment of Parkinson's disease. Levodopa can cross the blood-brain barrier that protects the brain. Once in the brain, it is converted to dopamine and thus can replace the dopamine lost in Parkinson's disease.
Mentioned in: Movement Disorders
References in periodicals archive ?
Since the introduction of L-dopa in the late 1960s, researchers have known that the body's enzymes (tools that perform necessary chemistry) can break down L-dopa in the gut, preventing the drug from reaching the brain.
To test whether the primary anti-DOPA antibody specifically binds L-DOPA, we used a strategy of pre-incubating pure L-DOPA antigen with the primary antibody prior to introducing this mixture to the fixed tissue, as in the standard protocol described above.
Conclusion: L-dopa is an effective treatment for bringing positive personality and cognition related changes in patients with idiopathic PD.
In Pakistan, PD patients are given L-dopa as a mono-therapy or with combination of other pharmacological agents such as benserzide, anticholinergics etc.6 A recent study with Pakistani population showed high prevalence of cognitive deficits in patients with PD.7 Few studies have shown L-dopa beneficial effects on motor function, alertness, cognitive and neuropsychological performance of patients with PD.8,9 There is a missing link in previous literature about L-dopa response to cortical functioning, health related quality of life and fatigue severity in patients with I-PD.
6-OHDA lesioned rats which had severe dopaminergic denervation-treated with L-dopa (Complete/L-dopa) (n=6)
Then a 120 [micro]L of an L-dopa solution (0.0625 to 0.25 mM) in a sodium phosphate buffer (pH 6.8) was added to initiate the reaction.
Among the central dopaminergic side effects of L-dopa, hallucinations and psychotic symptoms can cause important problems.
During L-DOPA treatment, body weights were recorded weekly till the end of the experiment for all the groups.
The effect of fumarprotocetraric acid on L-DOPA oxidation mediated by tyrosinase was evaluated spectrophotometrically (Bioespectro SP220) at 475 nm.
Wang 2002 basal bladder pressure in L-dopa injected group (p < 0.05 versus normal saline injected group).
The substrate was L-dopa by 120 [micro]L 0.1 mM in a sodium phosphate buffer at pH 6.8.
The samples were transferred to and incubated in fresh PBS with 1 mg/ml L-3,4-dihydroxyphenylalanine (l-DOPA; Sigma) for 90 min at 30[degrees]C, and then washed in distilled water (Zhang & Li 2000).